Schizophrenia Clinical Trials in Irvine
View 38 new treatments for Schizophrenia in Irvine, CA, and other areas near me, such as Anaheim, Costa Mesa, Murrieta, Orange, Santa Ana and Temecula. Every day, Power helps hundreds of schiz patients connect with leading medical research.RL-007 for Cognitive Impairment in Schizophrenia
Recognify Life Sciences Clinic, Orange + 13 more
This trial is testing a new drug, RL-007, to see if it can help people with schizophrenia think and remember better. The study will compare different doses of the drug and check for any side effects. Participants will take the drug for several weeks and complete memory and thinking tests before and after the treatment.Show More
Verified
Oxytocin for Schizophrenia
Research Clinic, Los Angeles + 1 more
This study will measure whether the engagement of intranasal oxytocin with a brain target is related to effects on learning during a social cognition training program.Show More
Clozapine for Schizophrenia
Research Clinic, Los Angeles + 1 more
This trial is testing whether clozapine can reduce violent behavior more effectively than usual treatments in adults with schizophrenia who have recently been violent. Clozapine helps by balancing brain chemicals to manage symptoms. The study will last for several months and include regular medical check-ups. Clozapine has been shown to reduce violent and aggressive behavior in patients with schizophrenia, especially those who are treatment-resistant.Show More
No Placebo Trial
KarXT for Schizophrenia
Karuna Clinic, Orange + 21 more
This trial tests KarXT, a combination of two drugs, for people who haven't improved with their current treatment. KarXT aims to balance brain functions and reduce side effects. The study will look at improvements in health and daily life. KarXT has shown positive results in earlier tests.Show More
Lumateperone for Schizophrenia and Bipolar Disorder
Intra-Cellular Therapies Clinic, Colton + 3 more
This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia or bipolar disorder.Show More
No Placebo Trial
Cariprazine for Adolescent Schizophrenia
Allergan Clinic, Culver City + 1 more
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Long-term Safety of Iclepertin for Schizophrenia
Boehringer Ingelheim Clinic, Costa Mesa + 14 more
This study is open to adults with schizophrenia who took part in a previous CONNEX study (study 1346-0011, 1346-0012, or 1346-0013). The purpose of this study is to find out how well people with schizophrenia can tolerate a medicine called Iclepertin in the long term. Participants take Iclepertin as tablets once a day for 1 year. In addition, all participants take their normal medication for schizophrenia. Participants are in the study for a little more than 1 year. During this time, they visit the study site about 13 times and get about 9 phone calls from the study team. The doctors collect information on any health problems of the participants. Doctors also regularly check the participants' symptoms of schizophrenia.Show More
No Placebo Trial
Brilaroxazine for Schizophrenia
Reviva Clinic, Garden Grove + 2 more
This trial tests Brilaroxazine, a daily pill, in patients with severe mental health issues. It aims to improve mood and reduce symptoms. The study lasts for more than a year.Show More
SEP-363856 for Schizophrenia
Sunovion Clinic, Anaheim + 4 more
This trial is testing a new schizophrenia medication called SEP-363856 in people who have already started using it. The goal is to see if it is safe and effective over several months. The medication works by affecting brain chemicals to help reduce symptoms of schizophrenia.Show More
No Placebo Trial
KarXT for Schizophrenia
Karuna Clinic, Los Alamitos + 4 more
The purpose of this study is to assess the safety and efficacy of slowly increasing dose and food effect of KarXT in adult participants with schizophrenia.
No Placebo Trial
Frequently Asked Questions
How much do schizophrenia clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.
Do I need to be insured to participate in a medical study?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
How do schizophrenia clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across schizophrenia trials in Irvine, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for schizophrenia patients is 6 Months.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.